ENGN
HEALTHCAREenGene Holdings Inc
$8.85+0.96 (+12.17%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ENGN Today?
No stock-specific AI insight has been generated for ENGN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.70$12.25
$8.85
Fundamentals
Market Cap$593M
P/E Ratio—
EPS$-2.25
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume389K
Avg Volume (10D)—
Shares Outstanding67.0M
ENGN News
20 articles- enGene Bladder Cancer Data Shows Promise, but Durability Questions RemainMarketbeat·May 8, 2026
- enGene Therapeutics (ENGN) Is Down 76.3% After Mixed LEGEND Phase 2 Durability Data Release Has The Bull Case Changed?Yahoo Finance·May 8, 2026
- enGene Therapeutics hit by analyst downgrades as drug data disappointsYahoo Finance·May 8, 2026
- enGene Announces Updated Interim Results From LEGEND Pivotal CohortYahoo Finance·May 7, 2026
- enGene Announces Name Change to enGene Therapeutics Inc.Yahoo Finance·Apr 7, 2026
- enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at ConferenceMarketbeat·Mar 15, 2026
- enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays ConferenceMarketbeat·Mar 15, 2026
- enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data UpdateMarketbeat·Mar 15, 2026
- enGene Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·Mar 9, 2026
- enGene Maps BLA by End-2026, Targets 2027 Launch for Lead NMIBC Therapy at Oppenheimer ConferenceMarketbeat·Feb 28, 2026
- enGene to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 20, 2026
- Jefferies Sets a $28 PT for enGene Holdings Inc. (ENGN)Yahoo Finance·Feb 16, 2026
- enGene CEO Talks Detalimogene for Community Urology as LEGEND Study Hits Full EnrollmentMarketbeat·Feb 12, 2026
- enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026Yahoo Finance·Feb 4, 2026
- Both private equity firms who control a good portion of enGene Holdings Inc. (NASDAQ:ENGN) along with institutions must be dismayed after last week's 16% decreaseYahoo Finance·Feb 2, 2026
- Spotify upgraded, Pinterest downgraded: Wall Street's top analyst callsYahoo Finance·Jan 30, 2026
- enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.Yahoo Finance·Jan 20, 2026
- enGene Reports Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Dec 22, 2025
- Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of DirectorsYahoo Finance·Dec 16, 2025
- enGene Holdings Inc (ENGN) Surging After Positive Phase 2 LEGEND TrialYahoo Finance·Dec 5, 2025
All 20 articles loaded
Price Data
Open$7.95
Previous Close$7.89
Day High$9.00
Day Low$7.95
52 Week High$12.25
52 Week Low$1.70
52-Week Range
$1.70$12.25
$8.85
Fundamentals
Market Cap$593M
P/E Ratio—
EPS$-2.25
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume389K
Avg Volume (10D)—
Shares Outstanding67.0M
About enGene Holdings Inc
enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The company is headquartered in Saint-Laurent, Canada.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—